(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 33.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.26%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.29%.
Tg Therapeutics's revenue in 2026 is $616,287,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $146,930,761,228, with the lowest TGTX revenue forecast at $138,893,651,304, and the highest TGTX revenue forecast at $153,929,897,489. On average, 8 Wall Street analysts forecast TGTX's revenue for 2027 to be $183,002,741,376, with the lowest TGTX revenue forecast at $147,722,814,978, and the highest TGTX revenue forecast at $207,115,668,032.
In 2028, TGTX is forecast to generate $237,616,124,928 in revenue, with the lowest revenue forecast at $212,545,068,736 and the highest revenue forecast at $262,208,116,352.